Similarly, a Dkk1 neutralizing antibody (BHQ880A, Novartis) has shown striking effects in multiple myeloma by increasing bone formation and inhibiting tumor growth both in vitro and in vivo [82,83]. Here, DKK1 is linked to plasma cell myeloma.